You Don’t Need a PhD to Evaluate Longevity Biotech. You Need a Process.
A promising mechanism can still be attached to weak human evidence, an unrealistic valuation, a short cash runway, heavy dilution or a team that cannot execute. Over 52 weeks, learn the 25 questions that help you examine the whole company before excitement becomes conviction.
Inside the 52-week program:
✓ One real public or private company evaluation each week
✓ The same 25 questions across science, evidence, valuation, financing and execution
✓ Immediate access to 135 earlier company screens
✓ Nominate one company each month for possible future review
✓ 60-day money-back guarantee
WHY I BUILT THE 25-GATE PROCESS
The Science Can Be Brilliant. The Company Can Still Be a Bad Bet.
I’m a business owner, not a PhD or institutional biotech analyst. I invested $10,000 in one longevity biotech and another $10,000 in a second because the science and potential sounded exciting. Those experiences included a tax loss, and I realized I had evaluated the promise more carefully than the full company. The mechanism was only one part of the decision. I needed a consistent way to examine the evidence, valuation, financing, dilution, competition and ability to execute.
A company can have a fascinating mechanism and still be too early, overvalued, underfunded or poorly positioned. The 25-Gate process forces the questions a pitch can skip, including human evidence, differentiation, cash runway, dilution and execution. Two hard gates stop a company from advancing when longevity relevance or the financial case does not justify continued research.
Each week, learn one healthy-aging mechanism, examine a real public or private company and apply the same 25 questions. See what is supported, what is assumed and what is still missing. By week 52, the goal is not a list of 52 stock tips. It is a repeatable evaluation process you can use when a new longevity-biotech opportunity crosses your desk.
For investors: Recognize missing evidence, financing constraints, dilution exposure and execution gaps before excitement hardens into conviction.
For founders and operators: Anticipate the questions investors are likely to ask, identify weaknesses before the pitch and explain what evidence or milestone would strengthen the case.
You do not begin with a blank course. Your membership opens the existing research record immediately: 135 company screens, 21 advanced for continued research, 114 did not, 5 later reached verified development milestones and 1 received a financing-risk warning. Inspect why each case advanced or stopped, then follow new weekly evaluations. Advanced means continued research attention, not a recommendation.
Who this program is for:
✓ Self-directed investors entering longevity biotech
✓ Generalist investors who are new to biotech
✓ Business owners, physicians and executives considering the field
✓ Aspiring founders and operators preparing to pitch
Not designed for experienced biotech funds with an established diligence process.
Join for $50/month or $299/year. Explore the complete program and archive for 60 days. If it is not useful, request a full refund of the amount paid.
Educational research and training only. Not a stock-picking service, investment advice or fundraising advice.